Understanding biosimilars, biologics, and the challenges surrounding their regulation and pricing in the pharmaceutical ...

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

While the pembrolizumab copy was eye-catching, the firm’s next big biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised to launch ...

Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...

The Q1 2025 biosimilar ASP discounts averaged 52% for trastuzumab, 49% for bevacizumab, and 66% for rituximab markets. The WAC discounts for supportive care biosimilars are between 18% and 67% ...

This marks the first U.S. BLA acceptance for a pertuzumab biosimilar, a targeted therapy ... by the FDA for use in combination with: 1) trastuzumab (HERCEPTIN) and docetaxel for treatment of ...